You are here

Article Text

Article menu
Download PDFPDF
Letter to the editor
End of the road for Essure?®
  1. David H Horwell1
  1. UK/Europe Advisory Editor, Journal of Family Planning and Reproductive Health Care, Retired Consultant Gynaecologist, Harpenden, UK
  1. ↵Correspondence to Dr David H Horwell; dhhjournal{at}mail.com

https://doi.org/10.1136/jfprhc-2017-101850

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I am writing to draw readers’ attention to a letter dated 31 May 2017 addressed to UK healthcare professionals from Bayer plc, in which that company announced that it had decided to discontinue sales of Essure®, their hysteroscopic female sterilisation device, from 1 September 2017.

    Essure uses metal and polyester fibre ‘microinserts’ that are passed into the proximal parts of the fallopian tubes to occlude them by fibrosis. It was approved for use in the USA in 2002 and in the UK by NICE, the National Institute for Health and Clinical Excellence, in 2009.1 The device was reviewed in this journal in …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.